Rhodiola Rosea for Fatigue

Verdict: Weak, conflicted evidence for fatigue

Rhodiola rosea has only weak and inconsistent evidence for fatigue: a handful of small, mostly industry-linked trials report benefits, but overall study quality is low and disease-relevant fatigue effects remain unproven. It may offer modest help for stress-related fatigue but is not a reliable or first-line remedy.

C 🟠 C Weak Evidence Published

🔬Why this grade7-layer evidence engine

This earns a Weak (Tier C) grade because the supporting human evidence is thin and conflicting. Three small double-blind RCTs of the proprietary SHR-5 extract - in stressed adults (PMID 19016404, n=60), night-duty physicians (PMID 11081987, n=56), and exam-period students (PMID 10839209) - reported improvements in fatigue, attention, and well-being. But all were small, relied on a single extract from one manufacturer, and at least one was industry-funded, which limits how far the results generalize.

Crucially, the only systematic review (PMID 22643043, Ishaque 2012) assessed 11 trials and judged the evidence contradictory: just 2 of 6 physical-fatigue and 3 of 5 mental-fatigue trials showed benefit, every study carried a high risk of bias, and outcomes were too heterogeneous to pool in a meta-analysis. Positive signals also cluster on surrogate measures such as attention rather than clinically meaningful fatigue.

Authorities are cautious rather than endorsing. The UK registers rhodiola only as a traditional herbal product based on long-standing use, not proven clinical efficacy, and the US FDA has issued warning letters against disease claims. NIH/NCCIH considers the evidence insufficient to conclude it works for any condition; Cleveland Clinic's general wellness page is more favorable but cites no graded evidence. Documented drug interactions add further reason for restraint.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.54
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
C · Published
Confidence
80%
Highly consistent evidence
Evidence level
E3
Single high-quality meta-analysis

How strongly each layer supports this effect

lower = less supportive
L1 ExamineGlobal benchmark
0.50
L11 AI re-checkIndependent read
0.50
L2 PubMedPrimary literature
0.60
L5 Clinical bodiesAuthoritative stance
0.62
L3 MechanismPlausibility
0.65
Against Mixed Supports
View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.537
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 高品質 SR/MA 顯示 positive (1 篇 > 0 negative)
  4. tier_strict_requirement_check — Tier 條件達標,未降階
  5. detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (4)L2 · primary research & systematic reviews

Rhodiola rosea for physical and mental fatigue: a systematic review (Ishaque et al., BMC Complement Altern Med)
PMID: 22643043 2012 系統性回顧
Finding: Of 11 included trials (10 RCTs, 1 CCT), only 2/6 physical-fatigue trials and 3/5 mental-fatigue trials showed benefit; evidence judged contradictory and all studies had high risk of bias or reporting flaws. No two studies used the same outcome, so meta-analysis was not possible.
View on PubMed
RCT of standardised extract SHR-5 of Rhodiola rosea in subjects with stress-related fatigue (Olsson et al.)
PMID: 19016404 2009 RCT (double-blind) n = 60
Finding: SHR-5 group showed significant improvement versus placebo in burnout symptoms, attention indices, and cortisol awakening response; depression/mental-health improved in both arms (placebo effect noted). Small single trial (n=60).
🟠 Limited quality ⚠️ Industry-funded
View on PubMed
Rhodiola rosea in stress-induced fatigue: double-blind cross-over study of SHR-5 in physicians on night duty (Darbinyan et al.)
PMID: 11081987 2000 RCT (double-blind) n = 56
Finding: Statistically significant improvement in Fatigue Index in the treatment group during the first two-week period versus placebo; no adverse effects. Small crossover trial, no p-value reported in abstract.
🟠 Limited quality
View on PubMed
Double-blind placebo-controlled pilot study of Rhodiola rosea SHR-5 on exam-period fatigue in students (Spasov et al.)
PMID: 10839209 2000 RCT (double-blind)
Finding: Significant improvement versus placebo in physical fitness, mental fatigue and neuro-motoric tests (p<0.01) and self-assessed well-being (p<0.05); no effect on text correction or tapping. Pilot study, sample size not stated in abstract, authors note dosing may be suboptimal.
🟠 Limited quality
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Cautious
Rhodiola rosea source↗
L4c UK NHS
Neutral
Rhodiola rosea L. is a plant that grows at high altitudes in the arctic areas of Europe, Asia and North America. It is a traditional herbal medicinal product registered in the UK for the treatment of mental and physical symptoms of stress and overwork, such as fatigue, exhaustion and mild anxiety. source↗
L4d TW TFDA / 衛福部
Neutral
紅景天列於食藥署「可供食品使用原料彙整一覽表」,學名包含 Rhodiola sacra、Rhodiola crenulata、Rhodiola rosea L.、Rhodiola sachalinensis,可供食品使用部位為根。臺灣中藥典亦收載紅景天(景天科大花紅景天之乾燥根及根莖),效能為益氣活血、通脈平喘,分類為補益藥(補氣)。 source↗
L5c Cleveland Clinic
Supportive
Rhodiola alleviates symptoms of fatigue, anxiety and depression. Studies show that rhodiola helps improve performance during stressful situations like at work or during physical activity. source↗
PMID 100% verifiedevery citation checked via NCBI Entrez
🔬4 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-fatigue-INT-rhodiola-rosea-001 繁體中文版 →